mProX™ Human CD70 Stable Cell Line

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

CD70 is a protein that has been studied in various applications. In clear cell renal cell carcinoma (ccRCC), the gene LINC00887 activates CD70 through the recruitment of SPI1, leading to malignant progression and cell stemness, while inhibiting T-cell chemotaxis. This suggests that targeting the LINC00887-SPI1-CD70 regulatory axis could be a potential breakthrough for treating ccRCC. In Santa Ines sheep, CD70 is associated with resistance to gastrointestinal nematodes, and its activation is linked to pathways and genes involved in the immune system and inflammatory response. In cancer treatment, a high-affinity humanized antibody called IMM40H targets CD70, eliminating tumors through Fc-mediated effector functions and interrupting CD70/CD27 signaling. In HIV infection, CD70 is involved in the differentiation of proinflammatory Th1/17/22/GM lymphocytes, which are associated with disease progression and immune reconstitution. Finally, in the context of solid tumors, CD70-specific CAR T cells have been studied using a bio-conjugated liquid-like solid medium, providing insights into CAR T cell function, immune trafficking, and infiltration in the tumor microenvironment.